{"public_id":"cl_a02c6e67686deb032ef706b16b0a6c4f","status":"active","superseded_by_public_id":null,"corpus_id":241185914,"text":"In children, trivalent live-attenuated vaccine (3-LAIV) and trivalent inactivated adjuvanted with MF59/AS03 were more efficacious than trivalent inactivated vaccine (3-IIV) in reducing laboratory-confirmed influenza (RR 0.52 and 0.23 respectively).","confidence":0.95,"paper":{"corpus_id":241185914,"title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis","url":"https://sah.borca.ai/papers/241185914"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_174b1e3b9ed85b1480baa02a8223f27f","name":"trivalent live-attenuated vaccine (3-LAIV)","description":"A live-attenuated trivalent vaccine that was less efficacious than 3-IIV in adults/elderly but more efficacious in children.","types":["vaccine type"],"url":"https://sah.borca.ai/concepts/co_174b1e3b9ed85b1480baa02a8223f27f"},{"public_id":"co_499f90d86287919c5257252e45d80fa7","name":"trivalent inactivated vaccine (3-IIV)","description":"The standard trivalent inactivated vaccine used as comparator in head-to-head analyses.","types":["vaccine type"],"url":"https://sah.borca.ai/concepts/co_499f90d86287919c5257252e45d80fa7"},{"public_id":"co_6fb5d11908ecb522d8f654589e40dda9","name":"trivalent inactivated adjuvanted with MF59/AS03 vaccine","description":"An adjuvanted trivalent inactivated vaccine that was more efficacious than 3-IIV in children (RR 0.23).","types":["vaccine type"],"url":"https://sah.borca.ai/concepts/co_6fb5d11908ecb522d8f654589e40dda9"},{"public_id":"co_a2c0954932fbf4fe3a282cabb18cd14b","name":"laboratory-confirmed influenza","description":"The primary outcome measure used in the review to assess vaccine efficacy.","types":["outcome","endpoint"],"url":"https://sah.borca.ai/concepts/co_a2c0954932fbf4fe3a282cabb18cd14b"},{"public_id":"co_e6d04be3c13f6c940520cdeec2cf0348","name":"children","description":"Population under 18 years old included in the review.","types":["population"],"url":"https://sah.borca.ai/concepts/co_e6d04be3c13f6c940520cdeec2cf0348"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a02c6e67686deb032ef706b16b0a6c4f"}